



**Tropical Disease
Foundation Inc.**

annual report

2017-2018



*I*ntroduction

This year marks the Tropical Disease Foundation, Inc.'s 34th founding anniversary. Looking back from the past, it is important to recognize the desire of TDF to continue its mission in the pursuit of excellence in the field of medical research.

TDF is grateful for the continued support of sponsors, stakeholders, partners and collaborators to handle and implement projects and clinical trials related to tuberculosis. The trust bestowed has been its driving force to deliver quality healthcare service and achieve its vision of equitable access to health for national prosperity.



Among the new projects TDF has been entrusted with this year is the Community Engagement Project sponsored by Global Alliance for TB Drug Development USA. This involves activities in augmenting community participation in TB research through planning, cooperation, and providing health education to community health workers. Target recipients of the project are Ospital ng Makati, Makati City and Pateros Community Health Workers.

A clinical trial on “Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis” involving the TDF Laboratory as the central laboratory of 4 sites. On the other hand, the TDF Clinic is one the clinical trial site to support the study.

While new opportunities for TDF are coming its way, efforts to continuously upgrade its standards in its provision of service and administrative capacity are being undertaken. This year, TDF started the foundation-wide house cleaning to determine areas of concerns that need immediate updating. An assessment of existing tools and development of new tools to better guide its employees in performing better is also being focused on.

We continue to give back glory to our Almighty God as we look forward to celebrating TDF’s 35th anniversary next year.



About TDF

The Tropical Disease Foundation, Inc. is a private, non-stock, non-profit, non-government organization founded in 1984 by a group of physicians in the Research Institute for Tropical Medicine. The founding chairman was Dr. Jesus Azurin, then Secretary of Health. The TDF began a legacy of quality research, service and training in infectious diseases.

Our Vision & Mission

The Tropical Disease Foundation, Inc. believes in equitable, universal access to health for economic prosperity. Its programs and projects encourage participation in the national and local communities through its research, training, health care service provision and advocacies.

Our Thrusts

1. To conduct research, training and service in infectious diseases of public health importance
2. To enter into partnership with public and private agencies in the implementation of programs in the control of infectious diseases
3. To ensure technology transfer in developing human resources for health nationally and internationally through collaboration with national and international institutions
4. To serve as a national and international training center for infectious diseases



PROJECTS / 2017-2018

Clinic

1. DOTS Clinic

The Tropical Disease Foundation, Inc. maintains a DOH-Certified TB DOTS Center facility in cooperation with the Makati City Health Department and National TB Program of the DOH's Infectious Disease Office. It aims to prevent and eliminate the spread of tuberculosis (TB), the most common communicable disease in the Philippines, through Directly Observed Treatment, Short-Course strategy (DOTS).

TDF offers a public-private mixed DOTS clinic for patients who have symptoms suggestive of TB or who are suspected to have tuberculosis by healthcare providers. DOTS is the most effective means of controlling the spread of tuberculosis and by involving the public and the private sector, case-finding and engagement to treatment is intensified.



TDF TB-DOTS Clinic caters to patients who live or work within its catchment area. These are walk-in patients or referrals by physicians of nearby hospitals such as Makati Medical Center, diagnostic clinics, schools, business establishments and offices. Patients diagnosed in TDF DOTS clinic but are living outside the catchment area are transferred to another DOTS facility near their residence for easier access to anti-TB drugs. Clinic operation is extended from early morning until late in the afternoon to accommodate the working sector.

TDF is at one with the country in its aim to attain health-related Sustainable Development Goals by serving more TB patients in the future.

Sponsoring Organization:

TB kits (drugs) and laboratory supplies are provided by Department of Health through the Makati City Health Department.

Objectives:

1. Improve the continuum of effective and quality care of TB symptomatics and TB patients.
2. Make treatment and quality services accessible to TB patients.
3. Timely results for prompt initiation of treatment.



Accomplishments:

- | | | |
|---|--------------------------------|-----------|
| • | NO. OF PATIENT SCREENED | 38 |
| • | NO. OF PATIENT ENROLLED | 18 |

Number of Patient Completed Treatment

- | | | |
|---|----------------------------|-----------|
| • | CURED | 2 |
| • | TREATMENT COMPLETED | 10 |
| • | LOSS TO FOLLOW-UP | 1 |
| • | ONGOING TREATMENT | 5 |

PhilHealth Claims:

In April 2018, TDF TB-DOTS Clinic started to utilize the Electronic Claim Submission Program (E-Claims Project) through PhilHealth Circular No. 14 and Office Order No. 69. This project aims to improve the current claim transaction between Health Care Units (also known as Institutional Health Care Providers) and the Government. Easy Claims allows you to check the status and submit claims electronically to PhilHealth without the need for manual submission of requirements.

The proceeds from Philhealth claims are utilized by TDF to maintain the operation of its treatment facility.



2. TDFI– Satellite Treatment Center (STC) for MDR-TB (Multi-Drug Resistant Tuberculosis)

The performance of the Satellite Treatment Center under the Programmatic Management of Drug-Resistant TB (PMDT) in the past year is as follows:

NUMBER OF PRESUMPTIVE DR-TB SCREENED	410
NUMBER OF ALL PRESUMPTIVE DR-TB TESTED	409
NUMBER OF ALL CONFIRMED RIFAMPICIN RESISTANT TB	35
NUMBER OF CASES REGISTERED	39
• BACTERIOLOGICALLY-CONFIRMED RR/MDR-TB	32
• CLINICALLY-DIAGNOSED MDR-TB	6
• OTHER DRUG-RESISTANT TB CASE	1

As of 31 July 2018, the clinic census is at 37 patients. This includes patients decentralized to the health centers, as well as patients started on treatment by Integrated DOTS (iDOTS) centers.

The STC currently has two (2) Philippine Business for Social Progress-hired nurses on board. Since September 2017, in compliance with an NTP directive, the STC has begun implementing the “No Drug Holiday” policy, necessitating the STC to be open even on Sundays and Holidays.



In recent months, the number of presumptive Drug-Resistant TB patients screened and patients registered at TDF-STC has steadily decreased as a result of the opening of the Rapid TB Diagnostic Laboratory at East Rembo Health Center and the West Rembo PMDT STC. Currently, TDF-STC primarily serves patients screened on-site who opt to undergo treatment with our facility. Since April 2018, patients started on treatment in the iDOTS centers are now registered in the West Rembo STC DRTB register.

3. STAND* Clinical Trial

*(Shortening Treatment by Advancing Novel Drugs)

Protocol Title

“A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear Positive Pulmonary Tuberculosis.”

Study Protocol No.: NC-006 (M-Pa-Z) —NC-006

Protocol Name: STAND

IRB Protocol No.: TDF 2014-04

Sponsor: Global Alliance for TB Drug Development USA



Study Milestones:

- ▶ Site Initiation visit:23-24 March 2015
- ▶ Date of first subject enrolled:19 May 2015
- ▶ Date of last subject enrolled: 17 Sep 2015
- ▶ Study Suspension:..... 25 Sep 2015
- ▶ Last Subject Completed:29 Aug 2017
- ▶ Database Lock: 31 Jan 2018
- ▶ Close-out Visit:..... 13 Mar 2018

Site Enrolment:

Overall, the summary of the site's accomplishment is presented below.

SCREENED/CONSENTED	17
SCREEN FAILED	7
RANDOMIZED	10
EARLY WITHDRAWN*	2
COMPLETE TRIAL	10

*Early Withdrawn patients also completed the Month 24 follow-up period.

Of the ten (10) randomized patients, two (2) were Early Withdrawn due to mono-resistance to Isoniazid after screening using an indirect susceptibility



test in liquid culture. These patients still completed their treatment and study follow-up visits up to Month 24. All patients who were randomized on four (4) and six (6) months of treatment have completed their treatment with a total of 18 scheduled site visits starting from day one (1) (baseline). There were no relapse and serious adverse events reported during the study conduct.

Trial hold summary

On September 25, 2015, the study was suspended as recommended by Data Safety Monitoring Committee (DSMC). The patient continuously receives the study medications while closely monitoring them for adverse events attributable to liver toxicity.

On Dec 2016, the DSMC suggested that enrolment hold be lifted however TB Alliance has made a decision not to re-start the enrollment for NC-006. During the STAND enrolment-hold, a different Phase 2b study using a different regimen (BPamZ) demonstrated superior efficacy compared to the regimen used by the STAND study (MPaZ). Hence, TB Alliance decided not to resume recruitment for the STAND trial.. TB Alliance is, therefore, currently planning a Phase 3 trial of this new regimen with the intention to use many of the same sites and infrastructure planned and developed for STAND for this new trial.

Global Recruitment

Globally, there are a total of 332 patients enrolled in the study (15 Multi Drug-Resistant and 317 Drug-Sensitive TB patients).



4. TRUNCATE-TB Clinical Trial

Protocol Title

“Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis”

Protocol Name:	TRUNCATE-TB
IRB Protocol No.:	MMCIRB 2016-100
Sponsor:	University College London (UCL) / National University Hospital (NUH) Singapore
Trial Duration:	Approximately 5 years

Objectives

1. The primary aim is to test the hypothesis that the TRUNCATE-TB management strategy is non-inferior to the standard TB management strategy assessed by the proportion of patients with unsatisfactory outcome at 2 years after randomisation.
2. The secondary aim is to assess the possible advantages of the TRUNCATE-TB management strategy compared to the standard management strategy from the patient perspective, the programme perspective and to assess cost-effectiveness.



3. Other aims are to evaluate the pharmacokinetics, microbiological efficacy and toxicity of a number of boosted 8-week regimens compared to standard treatment.

Study Updates

- ▶ Ethics Committee Initial Approval: 19 Jan 2017
- ▶ Investigators meeting: 18 Sep 2017
- ▶ Investigational Product Arrival:.....08 Feb 2018
- ▶ Coordinators meeting:.....09 Feb 2018
- ▶ Site Initiation visit:12 Feb 2018
- ▶ First subject enrolled:13 Apr 2018



Investigators Meeting at The Peninsula Manila



Coordinators Meeting at Lung Center of the Philippines on Feb 9, 2018



TDF Site Initiation Visit on Feb 12, 2018



5. Community Engagement Ongoing Project

Sponsor: Global Alliance for TB Drug Development USA

Grant Period: Apr 15, 2017 to Dec 31, 2018

Background

For several years now, TDF, being a research foundation, has continuously worked with different stakeholder on various clinical trials for new drugs and TB treatment regimen, implemented operational researches and participated in demonstration projects for new TB diagnostic technologies.

The TDF through a grant from the Global TB Alliance proposed to conduct a Community Engagement project to increase people's awareness on TB and its control in the target population of the community. The project also aims to uplift the spirit of the community on the fight against TB by providing updates on the national program being done about TB diagnosis and treatment. The information campaign will include latest researches being conducted by the foundation in order to help the program achieve its goal.

General Objective:

To augment community participation in TB research through planning, cooperation, and providing health education to community health workers.



Specific Objectives

1. To identify target communities for health education through the establishment of a cooperation with the local government unit (LGU)
2. To identify, together with local government and community health workers, the focal point for health education (infection control and prevention, case finding, or case holding)
3. To conduct a seminar on the focal point identified by the community
4. To increase community awareness on focal points determined for health-teaching
5. To determine community perception of research studies through education on studies currently being done on TB .

Events/Activities:

Date	Engagement Activity	Attendees Number	Topics Covered
18 OCT 2017	Meeting with Ospital ng Makati	9	<ul style="list-style-type: none"> • CE Project presentation • Topics for Health-teaching discussion
29 NOV 2017	Meeting with Pateros Health Department	15	<ul style="list-style-type: none"> • CE Project presentation • Topics for Health-teaching discussion
23 MAR 2018	Meeting with Makati Health Department	11	<ul style="list-style-type: none"> • CE Project presentation • Topics for Health-teaching discussion
19-20 APR 2018	Training with CHWs	58	<ul style="list-style-type: none"> • Case finding • Contact Tracing • Community Research Participation



Meeting with Ospital ng Makati Officials



Meeting with Pateros Municipal Health Officials



Meeting of Makati Health Officials together with TDF representatives, Dr. Rholine Gem Martin Veto and Mr. Glenn Balane



Training of Makati Community Health Workers (TB Task Force)



6. TB ALLIANCE WORLD TB DAY Mini-Grant

Sponsor: Global Alliance for TB Drug Development USA

Date of Event: March 5-9, 2018

Venue: University of Makati

The activity started by putting up the World TB Day Booth. The “Takpan ang Ubo Jingle” was played to catch attention to the booth. Students were given the chance to take home TB flyers and tissues with the TDF TB Hotline inscribed. TDF nurses answered questions from students and employees.











Those who were not able to get materials from the booth signed up to attend the TB 101 seminar.




Many questions were thrown in which the speaker responded to.



Former TB patient Louie Teng shared her experiences and works on TB. Some students who were inspired by her story even took pictures with her.



Dr. Rholine Gem Veto ended his lecture with a call for the students and the staff to be leaders for TB-free Philippines.



The attendees were given flyers, tissues and ballers.





Activities & Trainings

WORLD TB DAY 2018

Wanted: Leaders for a TB-free Philippines

Commemorating World TB Day / 18 March 2018, Quezon Memorial Circle



Ceremonial Signing: Pledge of Support to PhilSTEP with our Director for Administration, Ms. Leilani Naval



TREAT-TB Training Course for Nurses



Ms. Ma. Begonia Baliwagan, Head Nurse, TDFI representative for TREAT-TB Course for Nurse, Improving MDR-TB Control in the Philippines at Richmond Hotel, Ortigas from March 22-24, 2018

Community Engagement Forum



Ms. Ma. Begonia Baliwagan, TDF Head Nurse, attended Community Engagement Forum at Garden Court Marine Parade Durban, South Africa from June 10-12, 2018



Site Visit at Inanda-Seminary Clinic





Laboratory Clinical Trials

1. NC-006-(M-Pa-Z) STAND (Shortening Treatment by Advancing Novel Drugs)

A phase 3, open-label, partially randomized trial to evaluate the efficacy, safety and tolerability of the combination of Moxifloxacin plus PA-824 (Pretomanid) plus Pyrazinamide after 4 and 6 months in adult subjects with drug-sensitive smear-positive pulmonary Tuberculosis and after 6 months of treatment in adults subjects with multi-drug resistant, smear-positive pulmonary Tuberculosis.

Sponsor: Global Alliance for New TB Drug Development

Description

The Shortening Treatments by Advancing Novel Drugs (STAND) clinical trial is a phase 3 trial of the PaMZ regimen used to treat pulmonary tuberculosis. TDF laboratory serves as the central laboratory for four clinical sites in the



Philippines: TDF, LCP, QI, and PGH. As the central laboratory, TDF performs screening evaluation of sputum by AFB smear microscopy (using ZN method) and molecular tests (using HAIN MTBDRplus and HAIN MTBDRsl) to determine susceptibility of *M. tb* complex to rifampicin and/or fluoroquinolones. Bactec MGIT 960 system is used as the culture method for *M. tb* complex isolation. DNA extraction for molecular testing of Pyrazinamide susceptibility is also done at TDF. DNA extracts are sent to the *pncA* laboratory at Stellenbosch University in South Africa. LJ slopes and DNA extracts from LJ slopes are also sent to the central laboratory at the University College London (UCL) for speciation, MIC against Moxifloxacin and PA-824, MIRU strain typing, and susceptibility testing for Streptomycin, Rifampicin, Isoniazid, Ethambutol, Moxifloxacin and Pyrazinamide.

Update

A total of 22 patients for all sites were enrolled in the study from March 2015 up to September 2015. Of the 22 enrolled patients, three withdrew from the study. Due to safety concerns, enrollment of patients for the study was suspended on September 24, 2015. On December 13, 2016 TDF was informed that enrollment for the study is terminated. Enrolled patients will, however, continue with their treatment and scheduled laboratory works. Last specimen was submitted on October 25, 2017; a total of 889 samples were submitted to TDF laboratory for this trial.



2. TMC207-C211

A phase 2, open-label, multicenter, single-arm study to evaluate the pharmacokinetics, safety, tolerability and anti-mycobacterial activity of TMC207 in combination with a background regimen of multidrug resistant TB (MDR-TB) medications for the treatment of children and adolescents 0 months to <18 years of age who have confirmed or probably pulmonary MDR-TB.

Sponsor: Janssen Research and Development

Description

The TMC207-C211 clinical trial is a phase 2 clinical trial that aims to evaluate pharmacokinetics, safety, tolerability and anti-mycobacterial activity of Bedaquiline in combination with background regimen of MDR-TB drugs for children below 18 years of age. TDF laboratory acts as the central mycobacteriology laboratory for this study. As the central mycobacteriology laboratory, TDF performs TSpot TB Assay, GeneXpert, AFB (using Auramine O method), and culture using MGIT. DST profile is performed at the Institute of Tropical Medicine in Antwerp, Belgium.

Update

The first patient for the study was enrolled in January 2017. To date, a total of three subjects were enrolled, but one withdrew from the study. To date, 59 specimens were processed for the study.



3. TRUNCATE-TB (Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis)

A randomized, open-label, multi-arm, multi-stage (MAMS), parallel group strategy trial.

Sponsor: UCL is the trial legal sponsor and has delegated responsibility for the management of the trial to the National University Hospital (Singapore).

Description

This trial evaluates an alternative strategy of treating patients with DS-TB for two months with combinations including new drugs or optimized doses of currently available drugs, chosen for their sterilizing efficacy. TDF laboratory plays 3 major roles for the study, it acts: as the Central Mycobacteriology Laboratory, as a Site Laboratory for TDF, and as the Central Biorepository. As a central mycobacteriology laboratory, TDF performs: microscopy, TB culture, identification, DST, GeneXpert MTB/Rif assay, MIC, Resuscitating Promoting Factor testing, DNA extraction, and storage of isolates. As a site laboratory for TDF site, the laboratory performs: microscopy and GeneXpert MTB/Rif assay for screening patients. As the central biorepository, TDF stores clinical specimens from all sites of the study.



Update

First specimen was submitted last March 21, 2018. Enrollment of patients for the study is on-going and is expected to last up to December 31, 2018. The sponsors provided TDF with the following equipment: Ultralow Freezer (1 unit) and Sensitre equipment (1 set).

Laboratory Output (July 2017 to June 2018)

Month	Received			Processed						
	Sputum	Extra-pulmonary	Total	AFS	TBC	DST	DOTS	GeneXpert (OP)	GeneXpert (PMDT)	LPA
Jul-17	52	2	54	40	27	8	7	9	115	1
Aug-17	52	2	54	44	27	2	11	14	118	0
Sep-17	40	2	42	36	32	1	7	11	77	0
Oct-17	67	1	68	53	43	2	7	17	90	1
Nov-17	49	0	49	41	26	3	12	18	91	3
Dec-17	55	0	55	42	30	6	11	14	87	6
Jan-18	54	1	55	39	36	7	15	0	95	1
Feb-18	61	10	71	65	27	6	12	13	72	3
Mar-18	35	0	35	26	32	1	11	13	89	2
Apr-18	46	0	46	17	25	3	7	10	79	1
May-18	49	0	49	13	28	3	5	9	77	1
Jun-18	20	0	20	4	19	9	2	13	58	0
Total	580	18	598	420	352	51	107	141	1048	19



External Quality Assurance

1. GeneXpert EQA

Instrument #705175

DATE	RESULT
31-Aug-2017	Pass (8/8)
06-Sep-2017	Pass (8/8)
07-Nov-2017	Pass (8/8)
13-Apr-2018	Pass (8/8)

Instrument #812560

DATE	RESULT
08-Aug-2017	Pass (8/8)
07-Nov-2017	Pass (8/8)

2. LPA

MTBDRplus ver 2.0

DATE	RESULT
31-July-2017	28/28 (100%)
23-Oct-2017	28/28 (100%)
24-May-2018	17/18 (94.44%)

MTBDRsl ver 2.0

DATE	RESULT
31-July-2017	28/28 (100%)
20-Oct-2017	8/10 (100%)



3. INSTAND

AREA	DATE	RESULT
Microscopy	09-Oct-2017	100%
	02-Feb-2018	50%
Culture	23-Nov-2017	Good
	23-Mar-2018	75%
Identification	03-Nov-2017	100%
	02-Mar-2018	88%
DST	03-Nov-2017	Good
	02-Mar-2018	96%

4. IQLS

AREA	ITBC # 03	ITBC # 04
Microscopy	3.9	3.3
Identification	4	4
FLD	3.89	4
SLD	4	4
Average	3.95	3.83

*Perfect score: 4

5. UK NEQAS (IGRA)

ASSAY	SCORE
QFT-Gold Plus	2/2



EXTRAMURAL ACTIVITIES

1. HIV Proficiency Training

Ms. Elizabeth Kaye Corpuz attended the HIV Proficiency Training sponsored by PBSP last August 14 to 18, 2017. The training was held at the Manila Grand Opera Hotel, where the participants were housed for 5 days. The participants were trained to perform rapid diagnostic procedures for HIV testing. Certificates of proficiency were issued to applicants who passed both written and practical exams.

2. Good Clinical and Laboratory Practice Training

A Good Clinical and Laboratory Practice (GCLP) training was held at De La Salle Health Science Institute in Dasmariñas Cavite. It was entitled "Introduction to DAIDS GCLP". The activity was conducted on October 11-12, 2017 by FHI 360 (sponsored by DAIDS-NIH) as part of the preparations for the PHOENIX study. It was attended by: Norwin Gayle D. Martin, Rupert Rey J. Flores, and Marilou B. Salvaña.

3. Pollution Control Officers' Summit

The conference was attended by Pollution Control Officers of different institutions including TDF's PCO, Ms. Maita Deblois. It was organized by the Department of Environment and Natural Resources and was held on November 21-22, 2017 at the Manila Hotel. Several issues and updates on policies regarding waste management were discussed in the said summit.



4. PHOENIx/A5300B/I2003B Regional Training

As part of preparations for the PHOENIx study, a regional training was held at the Faculty of Medicine Siriraj Hospital, Mahidol University in Bangkok, Thailand on November 28-29, 2017. Anthony Geronimo and Glaiza Erika Guda attended the said training sponsored by ACTG network. Laboratory procedures and issues for the study were discussed in the said training.

5. Data Quality Check (DQC)

The activity was held at the H20 Hotel from January 24 to January 26, 2018. Ms. Norwin Gayle Martin attended the said activity, wherein data input from PMDT GeneXpert laboratories were validated. NTP updates were also discussed during the said activity.

6. World TB Day Activities

The laboratory department participated in the 2018 World TB Day activities held at the Quezon Memorial Circle last March 18, 2018. The laboratory was represented by Ms. Marilou Salvaña in the said event.

7. NTCBB Launching and Consultative Conference

The National Training Center for Biosafety and Biosecurity launch and consultative conference on the biosafety and biosecurity landscape in the Philippines were held last April 16-18, 2018 at the Crowne Plaza, Manila. Certified Biorisk Officers of the Philippines attended the conference and TDFI was represented by its Biosafety Officer, Mr. Anthony Geronimo. Several issues on biosafety and biosecurity were discussed on the conference.



8. Drug-Resistance Survey Training

The 2018 DRS training was held at the New World Manila Bay Hotel on April 26-27, 2018. It was attended by Ms. Norwin Gayle D. Martin. The protocol, workflow, forms, transport, and reporting for the study were discussed in the training. The roles of GeneXpert sites for the study were also discussed and TDF was assigned as the back-up GeneXpert laboratory for the city of Makati.

9. Cebu Velez General Hospital Visit and Training

On May 30, Anthony Geronimo and Elsie Marie Dela Cruz visited CVGH. Personnel from the said institution were trained and capacitated in the performance of assays for the TRUNCATE-TB trial.

10. Cebu Velez General Hospital Training

On July 3 and 4, Elsie Marie Dela Cruz and Elizabeth Kaye Corpuz conducted a hands-on training of CVGH personnel on TRUNCATE-TB laboratory procedures. The activity was a follow-up of the initial visit and training conducted last May 30.

11. 2nd Annual BRAP Convention: Laboratory Biosecurity in the Era of One Health

On July 5-6, Anthony Geronimo and Maita Deblois attended the 2nd Annual BRAP Convention entitled "Laboratory Biosecurity in the Era of One Health" at the Crowne Plaza Manila. Several issues and updates on biosecurity and biorisk management were discussed in the said convention such as: the Philippine National Biosafety and Biosecurity Framework, Risk Assessment, Laboratory Biobanking, Containment Facility Measures, and the Emerging and Re-emerging Diseases program of the Department of Health.



INTRAMURAL ACTIVITIES

1. Good Documentation Practice Training

Training on Good Documentation Practice was conducted at the 5th floor of the Philippine Institute of Tuberculosis Building last November 8, 2017. It was facilitated by the Laboratory Manager, Mr. Anthony Geronimo, and was attended by all laboratory staff of TDF. The training was conducted as part of the requirements of the NC-006 trial.

2. Makati Medical Center Fellow Training

Dr. Lasafin, a fellow from Makati Medical Center, was trained in different TB diagnostic procedures at TDF on November 2017. As part of the training, he rotated in different sections of the laboratory. Due to conflicts in schedule, Dr. Lasafin was not able to complete the training.

3. Basic Biosafety and Biosecurity Training

A basic biosafety and biosecurity training was conducted last April 10, 2018. It was facilitated by Anthony Geronimo and was attended by personnel from the laboratory department and the clinic department of TDF.



Capability and Technical Assistance

Employee

Title of Seminar

CORPUZ, ELIZABETH KAYE

HIV Proficiency Training

Aug. 14-18, 2017/

Manila Grand Opera Hotel, Manila

VETO, RHOLINE GEM MARTIN S.

Training on Standardized Shorter Treatment Regime

August 9-11, 2017 /

Ciudad Christia, San Mateo Rizal

VETO, RHOLINE GEM MARTIN S.

24th Annual PHILCAT Convention

August 17-18, 2017 /

Crown Plaza Galleria, Manila

VETO, RHOLINE GEM MARTIN S.

NTP Zonal Dissemination Form

September 22, 2017/ Tagaytay City

DALUZ, ABIGAIL S.

ANONAS, MARCO

Standardized Shorter Treatment Regime (SSTR) Training

October 10-13, 2017 / Ciudad Christia

Resort, Ampid, San Mateo, Rizal



MARTIN, NORWIN GAYLE
FLORES, RUPERT REY
SALVAÑA, MARILOU

GLCP Training

October 10-11, 2017 / Dela Salle Health
Science Institute / Dasmariñas, Cavite

DEBLOIS, MAITA B.

Pollution Control Officer Summit

November 21-22, 2017/ DENR, East Ave.,
Quezon City

GERONIMO, ANTHONY A.
GUDA, GLAIZA ERIKA B.

PHOENIX Training

November 27-30, 2017 / Thailand

MARTIN, NORWIN GAYLE DP
VETO, RHOLINE GEM MARTIN S.

PMDT Data Quality Check

January 24-26, 2018/
H2O Hotel, Manila

BELEN, JOVITA P.
CATINDIG, ANGELITO M.
CABANATAN, MA. LOURDES O.
CARIDAD, MA. TERESA A.
NUCUM, MARITA I.

TRAIN LAW Package I

February 21, 2018/
BIR Intramuros, Manila

JOSON, EVELYN S.

Data Privacy Act

March 15, 2018/ AIM Makati City



BALIWAGAN, MA. BEGONIA R.

**MDRTB Clinical Management
Training for Nurses**

March 22-24, 2018/ Richmonde Hotel,
Ortigas, Pasig City

GERONIMO, ANTHONY A.

**1st Conference for the Establishment
of the Biosafety & Biosecurity
Framework of the Philippines & the
Official Launching of the National
Training Center for Biosafety and
Biosecurity**

April 16-18, 2018 / Crowne Plaza,
Ortigas Ave., Quezon City

MARTIN, NORWIN GAYLE DP

**3rd Drug Resistance Survey Staff
Training for the TRUNCATE TB Trial**

May 30, 2018 / Cebu Velez Hospital,
Cebu City

BALIWAGAN, MARIA BEGONIA

Community Engagement Forum

June 10-12, 2018 / Garden Court Marine
Parade Durban, South Africa

BALIWAGAN, MARIA BEGONIA

South Africa TB Conference

June 12-15, 2018 / Durban, South Africa
International Convention Centre, South Africa



GERONIMO, ANTHONY A.
DEBLOIS, MAITA B.

**Biorisk Association of the
Philippines Inc.**

July 5-6, 2018/ Crown Plaza Galleria
Hotel, Ortigas Center

Trainings Provided:

DELA CRUZ, ELSIE MARIE
GERONIMO, ANTHONY A.

Training on the performance of assays

May 30, 2018 / Cebu Velez Hospital,
Cebu City

DELA CRUZ, ELSIE MARIE
CORPUZ, ELIZABETH KAYE

**Hands on training on TRUNCATE TB
laboratory procedures**

July 3-4, 2018 / Cebu Velez Hospital,
Cebu City

GERONIMO, ANTHONY A.

Basic biosafety & Biosecurity Training

April 10, 2018 / TDF 5th Floor

VETO, RHOLINE GEM MARTIN

TB 101

March 9, 2018/ University of Makati,
Makati City



The TDF Organization

Board of Trustees

Chairman

Dr. Florentino S. Solon

Members:

Dr. Thelma E. Tupasi

Dr. Florina R. Kaluag

Dr. Claver P. Ramos

Atty. Edwin Abella

Arch. Pablo R. Antonio, Jr.

Justice Manuel Lazaro

Ms. Mercedes A. Solon

Dr. Ruben Encarnacion



Executive Officers

**President
Dr. Thelma Tupasi**

**Chief Executive Officer
Dr. Roberta C. Romero**

**Director for Administration
Ms. Leilani C. Naval**



Management Staff

Laboratory Manager

Mr. Anthony A. Geronimo

Clinic Physician

Dr. Rholine Gem Martin S. Veto

Head Nurse

Ms. Ma. Begonia R. Baliwagan

Finance Manager

Ms. Jovita P. Belen

Human Resource Manager

Ms. Marita I. Nucum

General Services Manager

Ms. Marilou O. Gusic



REYES TACANDONG & Co.
FIRM PRINCIPLES. WISE SOLUTIONS.

BOA/PRC Accreditation No. 4782
December 29, 2015, valid until December 31, 2018
SEC Accreditation No. 0207-FR-2 (Group A)
September 27, 2016, valid until September 27, 2019

Cibbank Tower
5741 Paseo de Roxas
Makati City 1206 Philippines
Phone +63 982 9100
Fax +63 982 9111
Website www.reyestacandong.com

INDEPENDENT AUDITORS' REPORT

The Members and the Board of Trustees
Tropical Disease Foundation, Inc.
Philippine Institute of Tuberculosis Building
Amorsolo corner Urban Avenue
Barangay Pio Del Pilar, Makati City

Report on the Financial Statements

Opinion

We have audited the accompanying financial statements of Tropical Disease Foundation, Inc. (the Foundation), a non-stock, non-profit organization, which comprise the statements of assets, liabilities and fund balances as at July 31, 2018 and 2017, and the statements of revenues and expenses, statements of changes in fund balances and statements of cash flows for the years then ended, including a summary of significant accounting policies.

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Foundation as at July 31, 2018 and 2017, and its financial performance and its cash flows for the years then ended in accordance with Philippine Financial Reporting Standard for Small and Medium-sized Entities (PFRS for SME).

Basis for Opinion

We conducted our audits in accordance with Philippine Standards on Auditing (PSA). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Foundation in accordance with the Code of Ethics for Professional Accountants in the Philippines (Code of Ethics) together with the ethical requirements that are relevant to the audit of the financial statements in the Philippines, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with PFRS for SME, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING

Reyes Tacandong & Co. is a member of the RSM network. Each member of the RSM network is an independent accounting and consulting firm, and practices in its own right. The RSM network is not itself a separate legal entity of any description in any jurisdiction.



NOV 21 2018

RSM



- 2 -

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with PSA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with PSA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in manner that achieves fair presentation.



- 3 -

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

Report on the Supplementary Information Required Under Revenue Regulations Nos. 15-2010 and 19-2011 of the Bureau of Internal Revenue

Our audit was conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplementary information on taxes and licenses and the schedule of taxable income and deductible expenses in Note 21 to the financial statements is presented for purposes of filing with the Bureau of Internal Revenue and is not a required part of the basic financial statements. Such information is the responsibility of the management of the Foundation. The information has been subjected to the auditing procedures applied in our audit of the basic financial statements and in our opinion, the information is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

REYES TACANDONG & CO.

Pamela Ann P. Escudro
PAMELA ANN P. ESCUADRO

Partner

CPA Certificate No. 128829

Tax Identification No. 216-321-918-000

BOA Accreditation No. 4782; Valid until December 31, 2018

SEC Accreditation No. 1471-AR-1 Group A

Valid until June 4, 2021

BIR Accreditation No. 08-005144-013-2017

Valid until March 8, 2020

PTR No. 6607965

Issued January 3, 2018, Makati City

October 12, 2018

Makati City, Metro Manila



NOV 21 2018



TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF ASSETS, LIABILITIES AND FUND BALANCES

		July 31	
	Note	2018	2017
ASSETS			
Current Assets			
Cash	4	P7,667,803	P5,404,165
Receivables	5	1,923,489	1,425,981
Investments at fair value through profit or loss (FVPL)	6	124,591,536	147,984,748
Other current assets	7	321,153	286,624
Total Current Assets		134,503,981	155,101,518
Noncurrent Assets			
Available-for-sale (AFS) investments	8	58,824	60,480
Investment property	9	7,090,002	8,091,067
Property and equipment	10	68,000,128	70,802,052
Other noncurrent assets	11	1,165,366	286,939
Total Noncurrent Assets		76,314,320	79,240,538
		P210,818,301	P234,342,056
LIABILITIES AND FUND BALANCES			
Current Liability			
Accrued expenses and other payables	12	P5,203,894	P4,905,163
Noncurrent Liability			
Net retirement benefit liability	18	17,771,259	29,605,964
Total Liabilities		22,975,153	34,511,127
Fund Balances			
Operating fund		112,696,444	120,879,580
Capital fund		75,090,130	78,893,119
Reserve for fair value changes of AFS investments	8	56,574	58,230
Total Fund Balances		187,843,148	199,830,929
		P210,818,301	P234,342,056

See accompanying Notes to Financial Statements.





TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF REVENUES AND EXPENSES

	Note	Years Ended July 31	
		2018	2017
SOURCES OF FUNDS	14	₱9,862,759	₱9,353,114
PROGRAM EXPENSES	15	(26,698,890)	(33,201,844)
GENERAL AND ADMINISTRATIVE EXPENSES	16	(3,367,765)	(9,791,202)
OTHER INCOME	17	8,432,183	12,512,496
EXCESS OF EXPENSES OVER REVENUES BEFORE INCOME TAX		(11,771,713)	(21,127,436)
PROVISION FOR INCOME TAX	19		
Current		214,412	395,362
Deferred		-	(1,862)
		214,412	393,500
EXCESS OF EXPENSES OVER REVENUES		(11,986,125)	(21,520,936)
OTHER COMPREHENSIVE INCOME (LOSS)			
<i>Item to be reclassified to profit or loss when realized</i>			
Unrealized gain (loss) on fair value changes of AFS investments	8	(1,656)	3,600
TOTAL COMPREHENSIVE LOSS		(₱11,987,781)	(₱21,517,336)

See accompanying Notes to Financial Statements.



TROPICAL DISEASE FOUNDATION, INC.

(A Non-stock, Non-profit Organization)

STATEMENTS OF CHANGES IN FUND BALANCES

	Note	Years Ended July 31	
		2018	2017
OPERATING FUND BALANCE			
Balance at beginning of year		₱120,879,580	₱138,036,347
Excess of expenses over revenues		(11,986,125)	(21,520,936)
Transfer from capital fund	9, 10	7,314,592	7,380,441
Transfer to capital fund	10	(3,511,603)	(3,016,272)
Balance at the end of year		112,696,444	120,879,580
CAPITAL FUND BALANCE			
Balance at beginning of year		78,893,119	83,257,288
Transfer to operating fund	9, 10	(7,314,592)	(7,380,441)
Additions to property and equipment	10	3,511,603	3,016,272
Balance at the end of year		75,090,130	78,893,119
RESERVE FOR FAIR VALUE CHANGES OF AFS INVESTMENTS			
Balance at beginning of year		58,230	54,630
Unrealized gain (loss) on fair value changes of AFS investments	8	(1,656)	3,600
Balance at the end of year		56,574	58,230
		₱187,843,148	₱199,830,929

See accompanying Notes to Financial Statements.



TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CASH FLOWS

	Notes	Years Ended July 31	
		2018	2017
CASH FLOWS FROM OPERATING ACTIVITIES			
Excess of expenses over revenues before income tax		(P11,771,713)	(P21,127,436)
Adjustments for:			
Retirement benefit expense (income)	18	(11,834,705)	3,587,492
Depreciation	9, 10	7,314,592	7,380,441
Investment income	6	(5,806,788)	(9,652,745)
Advances written-off	5	86,531	-
Interest income	4	(14,979)	(18,234)
Gain on sale of property and equipment	17	-	(168,651)
Excess of expenses over revenues before working capital changes		(22,027,062)	(19,999,133)
Decrease (increase) in:			
Receivables		(584,039)	1,145,157
Other current assets		(34,529)	420,651
Deferred input VAT	11	(215,479)	(125,905)
Increase (decrease) in accrued expenses and other payables		298,731	(1,803,596)
Net cash used in operations		(22,562,378)	(20,362,826)
Income tax paid		(214,412)	(246,076)
Interest received		14,979	18,234
Net cash used in operating activities		(22,761,811)	(20,590,668)
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from:			
Withdrawals of investments at FVPL	6	29,200,000	17,095,360
Sale of property and equipment	10	-	168,651
Additions to property and equipment	10	(3,511,603)	(3,016,272)
Increase in advances to a supplier	11	(662,948)	-
Net cash provided by investing activities		25,025,449	14,247,739
NET INCREASE (DECREASE) IN CASH		2,263,638	(6,342,929)
CASH AT BEGINNING OF YEAR		5,404,165	11,747,094
CASH AT END OF YEAR		P7,667,803	P5,404,165

See accompanying Notes to Financial Statements.